Huntington Disease — A Pilot Evaluation of Mindfulness-based Cognitive Therapy for People With Huntington's Disease
Citation(s)
Aoun, S, Kristjanson, L, Oldham, L The Challenges and Unmet Needs of People with Neurodegenerative Conditions and their Carers. Journal for Community Nurses, 11(1): 17-20, 2006.
Arran N, Craufurd D, Simpson J Illness perceptions, coping styles and psychological distress in adults with Huntington's disease. Psychol Health Med. 2014;19(2):169-79. doi: 10.1080/13548506.2013.802355. Epub 2013 Jun 14.
Aubeeluck A, Buchanan H The Huntington's disease quality of life battery for carers: reliability and validity. Clin Genet. 2007 May;71(5):434-45.
Aubeeluck AV, Buchanan H, Stupple EJ 'All the burden on all the carers': exploring quality of life with family caregivers of Huntington's disease patients. Qual Life Res. 2012 Oct;21(8):1425-35. doi: 10.1007/s11136-011-0062-x. Epub 2011 Nov 13.
Bihari, J, Mullan, E Relating Mindfully: A Qualitative Exploration of Changes in Relationships Through Mindfulness-Based Cognitive Therapy. Mindfulness 5(1): 46-59, 2014.
Cairns V, Murray C How do the features of mindfulness-based cognitive therapy contribute to positive therapeutic change? A meta-synthesis of qualitative studies. Behav Cogn Psychother. 2015 May;43(3):342-59. doi: 10.1017/S1352465813000945. Epub 2013 Nov 11. Review.
Craufurd, D, Snowden, JS Neuropsychiatry and Neuropsychology. In G Bates, SJ Tabrizi, L Jones (Eds.), Huntington's disease (4th ed., pp. 36-65). Oxford: Oxford University Press. (2014)
Evans SJ, Douglas I, Rawlins MD, Wexler NS, Tabrizi SJ, Smeeth L Prevalence of adult Huntington's disease in the UK based on diagnoses recorded in general practice records. J Neurol Neurosurg Psychiatry. 2013 Oct;84(10):1156-60. doi: 10.1136/jnnp-2012-304636. Epub 2013 Mar 12.
Fitzpatrick L, Simpson J, Smith A A qualitative analysis of mindfulness-based cognitive therapy (MBCT) in Parkinson's disease. Psychol Psychother. 2010 Jun;83(Pt 2):179-92. doi: 10.1348/147608309X471514. Epub 2009 Oct 19.
Griffiths K, Camic PM, Hutton JM Participant experiences of a mindfulness-based cognitive therapy group for cardiac rehabilitation. J Health Psychol. 2009 Jul;14(5):675-81. doi: 10.1177/1359105309104911.
Jha AP, Stanley EA, Kiyonaga A, Wong L, Gelfand L Examining the protective effects of mindfulness training on working memory capacity and affective experience. Emotion. 2010 Feb;10(1):54-64. doi: 10.1037/a0018438.
Kaptein, A A, Helder, DI, Scharloo, M, Van Kempen, GMJ, Weinman, J, Van Houwelingen, HJC, Roos, RAC. Illness perceptions and coping explain well-being in patients with Huntington's disease. Psychology & Health, 21(4): 431-446. (2006)
Kay, C, Fisher, E, Hayden, MR Epidemiology. In G. Bates, S. J. Tabrizi & L. Jones (Eds.), Huntington's disease (4th ed., pp. 131-164). Oxford: Oxford University Press. 2014.
Lowit A, van Teijlingen ER Avoidance as a strategy of (not) coping: qualitative interviews with carers of Huntington's Disease patients. BMC Fam Pract. 2005 Sep 14;6:38.
Ma SH, Teasdale JD Mindfulness-based cognitive therapy for depression: replication and exploration of differential relapse prevention effects. J Consult Clin Psychol. 2004 Feb;72(1):31-40.
McCabe MP, Firth L, O'Connor E A comparison of mood and quality of life among people with progressive neurological illnesses and their caregivers. J Clin Psychol Med Settings. 2009 Dec;16(4):355-62. doi: 10.1007/s10880-009-9168-5. Epub 2009 Jul 29.
Mestre TA, Ferreira JJ An evidence-based approach in the treatment of Huntington's disease. Parkinsonism Relat Disord. 2012 May;18(4):316-20. doi: 10.1016/j.parkreldis.2011.10.021. Epub 2011 Dec 16. Review.
O'Connor EJ, McCabe MP Predictors of quality of life in carers for people with a progressive neurological illness: a longitudinal study. Qual Life Res. 2011 Jun;20(5):703-11. doi: 10.1007/s11136-010-9804-4. Epub 2010 Dec 2.
Ree MJ, Craigie M A Outcomes following mindfulness-based cognitive therapy in a heterogeneous sample of adult outpatients. Behavior Change 24(2): 70-86, 2007.
Smith JA Interpretative phenomenological analysis : theory, method and research. London: Sage. 2009.
Spinney L Uncovering the true prevalence of Huntington's disease. Lancet Neurol. 2010 Aug;9(8):760-1. doi: 10.1016/S1474-4422(10)70160-5. Epub 2010 Jun 30.
Splevins K, Smith A, Simpson J Do improvements in emotional distress correlate with becoming more mindful? A study of older adults. Aging Ment Health. 2009 May;13(3):328-35. doi: 10.1080/13607860802459807.
Teasdale JD, Williams JMG, Segal, ZV The Mindful Way Workbook: An 8-week Program to Free Yourself from Depression and Emotional Distress. New York, New York: Guildford Press. 2014.
Videnovic A Treatment of huntington disease. Curr Treat Options Neurol. 2013 Aug;15(4):424-38. doi: 10.1007/s11940-013-0219-8.
Wachs K, Cordova JV Mindful relating: exploring mindfulness and emotion repertoires in intimate relationships. J Marital Fam Ther. 2007 Oct;33(4):464-81.
Interventional studies are often prospective and are specifically tailored to evaluate direct impacts of treatment or preventive measures on disease.
Observational studies are often retrospective and are used to assess potential causation in exposure-outcome relationships and therefore influence preventive methods.
Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.
Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.
Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.